The double dose plateletpheresis (DDP) is considered to be a cost effective way of preparing platelets, owing to the low incidence of infectious complications and by also minimizing allogeneic donor exposure to the patients. We aimed at collecting DDP at our center and study its effect on donor hematological parameters, evaluate the product quality and the adverse donor reactions thereafter. Double Dose Platelet was collected from 160 eligible apheresis donors on Amicus cell separator (Fenwal, Inc. Three Corporate Drive Lake Zurich, IL, USA). The donor hematological parameters, product yield, adverse effects on the donors, collection efficiency (CE) and collection rate of the machine were noted. A total of 160 DDPs were collected. The total blood volume processed to achieve the yield of 6.0 × 1011 was 3673.5 ± 276.56 mL. The average yield achieved was 6.14 ± 0.26 × 1011. The average run time was 68.05 ± 6.25 min. Total ACD used was 408.33 ± 33.81 mL. We observed significant relation of pre-donation donor platelet count and platelet yield ( < 0.001). The CE was 78.09 ± 5.15%. There was a significant drop in the post DDP platelet count ( < 0.01) causing no adverse effect. Fourteen donors (8.75%) experienced mild citrate related adverse events. DDP does not lead to major adverse effects and post DDP hematological parameters are also within the acceptable range. It also helps to maintain apheresis platelet inventory, reduce donor exposure, reduce donor requirement and reduce the cost of the product.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186238 | PMC |
http://dx.doi.org/10.1007/s12288-018-0920-6 | DOI Listing |
Brain Commun
January 2025
Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm 17165, Sweden.
Parkinson's disease is primarily marked by mitochondrial dysfunction and metabolic abnormalities. We recently reported that the combined metabolic activators improved the immunohistochemical parameters and behavioural functions in Parkinson's disease and Alzheimer's disease animal models and the cognitive functions in Alzheimer's disease patients. These metabolic activators serve as the precursors of nicotinamide adenine dinucleotide and glutathione, and they can be used to activate mitochondrial metabolism and eventually treat mitochondrial dysfunction.
View Article and Find Full Text PDFExpert Opin Investig Drugs
January 2025
Department of Pediatric Respiratory, Children's Medical Center,The First Hospital of Jilin University, Jilin, China.
Background: XKH001 is a recombinant humanized IgG1 monoclonal antibody against IL-25 for the treatment of type 2 inflammatory diseases. This study aimed to evaluate the tolerability, pharmacokinetics, and pharmacodynamics of XKH001 in humans for the first time.
Research Design And Methods: This clinical investigation adopted a randomized, double-blind, and placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) design.
Br J Gen Pract
January 2025
Amsterdam UMC Locatie Meibergdreef, Vrije Universiteit, Department of General Practice, Amsterdam, Netherlands.
Background: Low-dose amitriptyline and mirtazapine are widely prescribed off-label for insomnia disorder. However, evidence from placebo-controlled studies is lacking.
Aim: To assess the effectiveness of low-dose mirtazapine and amitriptyline in patients with insomnia disorder.
BMJ
January 2025
Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong province, China
Objective: To evaluate whether the immunomodulatory drug thymosin α1 reduces mortality in adults with sepsis.
Design: Multicentre, double blinded, placebo controlled phase 3 trial.
Setting: 22 centres in China, September 2016 to December 2020.
J Minim Invasive Gynecol
January 2025
Division of Urogynecology, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Present Affiliation (not associated with study): Department of Obstetrics and Gynecology, Cambridge Memorial Hospital, Cambridge, Ontario, Canada.
Objective: To determine the efficacy of intravenous (IV) tranexamic acid (TXA) in reducing blood loss and blood transfusion among women undergoing total colpocleisis.
Design: Double-blind, randomized, placebo-controlled trial.
Setting: Tertiary academic urogynecology practice.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!